SEC Form SC 13G filed by Myovant Sciences Ltd.

2/9/23 7:57:21 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MYOV alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No. 0 MYOVANT SCIENCES LTD COMMON STOCK Cusip #G637AM102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #G637AM102 Item 1: Reporting Person - FIL Limited Item 2: (a) [ ] (b) [ ] Item 4: Bermuda Item 5: 8,624,543 Item 6: 0 Item 7: 8,624,543 Item 8: 0 Item 9: 8,624,543 Item 11: 8.909% Item 12: FI Cusip #G637AM102 Item 1: Reporting Person - Pandanus Partners, L.P. Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 8,624,543 Item 8: 0 Item 9: 8,624,543 Item 11: 8.909% Item 12: PN Cusip #G637AM102 Item 1: Reporting Person - Pandanus Associates, Inc. Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 8,624,543 Item 8: 0 Item 9: 8,624,543 Item 11: 8.909% Item 12: CO Item 1(a). Name of Issuer: MYOVANT SCIENCES LTD Item 1(b). Address of Issuer's Principal Executive Offices: SUITE 1, 3RD FLOOR,11-12 ST. JAMES SQUARE London, X0 SW1Y 4LB UK Item 2(a). Name of Person Filing: FIL Limited Item 2(b). Address or Principal Business Office or, if None, Residence: Pembroke Hall, 42 Crow Lane, Hamilton, Bermuda, HM19 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: G637AM102 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FIL Limited, is a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J). (Note: See Exhibit A). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify type of institution: Parent holding or control person. Item 4. Ownership (a) Amount Beneficially Owned: 8,624,543 (b) Percent of Class: 8.909% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 8,624,543 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 8,624,543 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of MYOVANT SCIENCES LTD. No one other person's interest in the COMMON STOCK of MYOVANT SCIENCES LTD is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to FIL Limited and its various non-U.S. investment management subsidiaries included on this Schedule 13G is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institutions. I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 9, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of December 19, 2022, by and on behalf of FIL Limited and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FIL Limited on January 31, 2023, accession number: 0000318989-23-000005. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Investments Canada ULC * FI * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Pandanus Partners, L.P. ("Pandanus") owns shares of FIL Limited ("FIL") voting stock. While the percentage of total voting power represented by these shares of FIL voting stock may fluctuate as a result of changes in the total number of shares of FIL voting stock outstanding from time to time, it normally represents more than 25% and less than 48.5% of the total votes which may be cast by all holders of FIL voting stock. Pandanus Associates, Inc. ("PAI") acts as general partner of Pandanus. Pandanus is owned by trusts for the benefit of members of the Johnson family, including FIL's Chairman Abigail P. Johnson, but disclaims that any such member is a beneficial owner of the securities reported on this Schedule 13G. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FIL, certain of its subsidiaries and affiliates, and other companies (collectively, the "FIL Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FIL Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 9, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of MYOVANT SCIENCES LTD at December 30, 2022. FIL Limited By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of December 19, 2022, by and on behalf of FIL Limited and its direct and indirect subsidiaries* Pandanus Partners, L.P. By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of December 19, 2022, by Pandanus Associates, Inc. on behalf of Pandanus Partners, L.P.* Pandanus Associates, Inc. By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of December 19, 2022, by and on behalf of Pandanus Associates, Inc.* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FIL Limited on January 31, 2023, accession number: 0000318989-23-000005.

Get the next $MYOV alert in real time by email

Recent Analyst Ratings for

$MYOV

Date	Price Target	Rating	Analyst
10/26/2022		Outperform → In-line	Evercore ISI
8/9/2022	$12.00 → $23.00	Mkt Perform → Outperform	SVB Leerink
2/16/2022	$21.00 → $19.00	Market Perform	SVB Leerink
1/5/2022	$23.00 → $21.00	Market Perform	SVB Leerink
10/27/2021	$24.00 → $23.00	Market Perform	SVB Leerink
9/9/2021	$24.00	Market Perform	SVB Leerink
8/20/2021	$18.00	Neutral	Goldman

More analyst ratings

SEC Form SC 13G filed by Myovant Sciences Ltd.

Chat with this insight

Recent Analyst Ratings for
$MYOV

$MYOV
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Myovant Sciences Ltd. (Amendment)